Roivant Sciences (ROIV)
40.82
-0.12 (0.29%)
Upcoming Events
Latest Headlines
Form 4 Roivant Sciences Ltd. For: Sep 08 Filed by: Fitzgerald Meghan
September 10, 2026 9:01 PM - SEC Filing
Roivant Sciences (ROIV) PT Raised to $47 at H.C. Wainwright
September 9, 2026 7:25 AM - StreetInsider
Roivant Sciences (ROIV) PT Raised to $46 at Guggenheim
September 9, 2026 5:39 AM - StreetInsider
Roivant Sciences (ROIV) PT Raised to $55 at TD Cowen
September 9, 2026 5:38 AM - StreetInsider
Roivant Sciences (ROIV) PT Raised to $52 at Jefferies
September 8, 2026 10:53 AM - StreetInsider
Roivant Sciences (ROIV) PT Raised to $55 at Piper Sandler
September 8, 2026 9:47 AM - StreetInsider
Roivant's mosliciguat shows PVR reduction in phase 2 PH-ILD trial
September 8, 2026 6:01 AM - StreetInsider
Pulmovant's mosliciguat hits primary endpoint in PH-ILD phase 2 trial
September 8, 2026 6:00 AM - StreetInsider
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier S
September 8, 2026 6:00 AM - StreetInsider
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Stu
September 8, 2026 6:00 AM - StreetInsider
Pulmovant to present Phase 2 mosliciguat results at ERS Congress
September 6, 2026 1:00 AM - StreetInsider
Roivant to present Phase 2 mosliciguat data at ERS Congress Sept. 8
September 6, 2026 1:00 AM - StreetInsider
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on T
September 6, 2026 1:00 AM - StreetInsider
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on
September 6, 2026 1:00 AM - StreetInsider
Form 144 Roivant Sciences Ltd. Filed by: Venker Eric
August 28, 2026 4:33 PM - SEC Filing
Form 8-K Roivant Sciences Ltd. For: Aug 28
August 28, 2026 4:32 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)
August 28, 2026 6:49 AM - StreetInsider
Form 8-K Roivant Sciences Ltd. For: Aug 27
August 27, 2026 5:25 PM - SEC Filing
FDA approves Roivant's brepocitinib pill for dermatomyositis
August 27, 2026 3:29 PM - StreetInsider
FDA approves Priovant's brepocitinib for dermatomyositis treatment
August 27, 2026 3:29 PM - StreetInsider
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
August 27, 2026 3:29 PM - Globe NewsWire
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
August 27, 2026 3:29 PM - StreetInsider
FDA approves Priovant's brepocitinib for dermatomyositis
August 27, 2026 3:28 PM - StreetInsider
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
August 27, 2026 3:28 PM - Globe NewsWire
JAMA Dermatology publishes brepocitinib skin data from VALOR trial
August 26, 2026 11:12 AM - StreetInsider
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
August 26, 2026 11:11 AM - Globe NewsWire
Roivant Sciences (ROIV) Reiterated at Overweight by Cantor Fitzgerald: 'Thesis Unchanged'
August 25, 2026 7:39 AM - StreetInsider
Form 4 Roivant Sciences Ltd. For: Aug 20 Filed by: Pulik Richard
August 24, 2026 9:00 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Aug 20 Filed by: Venker Eric
August 24, 2026 9:00 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Aug 19 Filed by: Sukhatme Mayukh
August 21, 2026 9:01 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Sukhatme Mayukh
August 21, 2026 4:20 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Sukhatme Mayukh
August 20, 2026 4:35 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Sukhatme Mayukh
August 19, 2026 4:23 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Aug 14 Filed by: Sukhatme Mayukh
August 18, 2026 9:00 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Sukhatme Mayukh
August 18, 2026 4:30 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Sukhatme Mayukh
August 17, 2026 4:41 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Sukhatme Mayukh
August 14, 2026 4:27 PM - SEC Filing
Form SCHEDULE 13G/A Roivant Sciences Ltd. Filed by: MORGAN STANLEY
August 13, 2026 3:45 PM - SEC Filing
Roivant Sciences (ROIV) PT Raised to $50 at TD Cowen
August 6, 2026 3:15 PM - StreetInsider
Immunovant posts $153M net loss as R&D spending climbs in fiscal Q1
August 6, 2026 9:58 AM - StreetInsider
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
August 6, 2026 9:56 AM - StreetInsider
Form 10-Q Roivant Sciences Ltd. For: Jun 30
August 6, 2026 7:28 AM - SEC Filing
Roivant Sciences Ltd. (ROIV) Tops Q1 EPS by 4c
August 6, 2026 7:16 AM - StreetInsider
Form 8-K Roivant Sciences Ltd. For: Aug 06
August 6, 2026 7:14 AM - SEC Filing
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
August 6, 2026 7:01 AM - Globe NewsWire
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
August 6, 2026 7:00 AM - Globe NewsWire
Priovant enrolls first patients in Phase 3 cutaneous sarcoidosis trial
August 6, 2026 7:00 AM - StreetInsider
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
August 6, 2026 7:00 AM - StreetInsider
Roivant Sciences (ROIV) PT Raised to $35 at BofA Securities
July 31, 2026 5:13 AM - StreetInsider
Form 4 Roivant Sciences Ltd. For: Jul 27 Filed by: Venker Eric
July 29, 2026 9:00 PM - SEC Filing
Form ARS Roivant Sciences Ltd. For: Mar 31
July 29, 2026 7:02 AM - SEC Filing
Form DEFA14A Roivant Sciences Ltd.
July 29, 2026 7:01 AM - SEC Filing
Form DEF 14A Roivant Sciences Ltd. For: Sep 16
July 29, 2026 7:01 AM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Venker Eric
July 27, 2026 4:16 PM - SEC Filing
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
July 23, 2026 4:05 PM - StreetInsider
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
July 23, 2026 4:05 PM - StreetInsider
Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: Epperly Melissa B,
July 21, 2026 9:00 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: MOMTAZEE JAMES C
July 21, 2026 9:00 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jul 17 Filed by: Oren Ilan
July 21, 2026 9:00 PM - SEC Filing
Arbutus sues Pfizer and BioNTech over LNP patents in 3 countries
July 16, 2026 7:30 AM - StreetInsider
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to
July 16, 2026 7:30 AM - StreetInsider
Form 4 Roivant Sciences Ltd. For: Jun 30 Filed by: Gline Matthew
July 2, 2026 7:06 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 30 Filed by: Fitzgerald Meghan
July 2, 2026 7:04 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 30 Filed by: Torti Frank
July 2, 2026 7:01 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 30 Filed by: Sukhatme Mayukh
July 2, 2026 7:00 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 29 Filed by: Epperly Melissa B,
July 1, 2026 6:34 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 26 Filed by: MANCHESTER KEITH S
June 30, 2026 8:38 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 26 Filed by: Gold Daniel Allen
June 30, 2026 8:30 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 26 Filed by: QVT Financial LP
June 30, 2026 7:59 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Fitzgerald Meghan
June 30, 2026 4:36 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: MANCHESTER KEITH S
June 30, 2026 4:26 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 25 Filed by: Sukhatme Mayukh
June 29, 2026 6:23 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Epperly Melissa B,
June 29, 2026 4:41 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 24 Filed by: Venker Eric
June 26, 2026 6:14 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Sukhatme Mayukh
June 26, 2026 4:10 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Sukhatme Mayukh
June 25, 2026 4:34 PM - SEC Filing
Form 144 Roivant Sciences Ltd. Filed by: Venker Eric
June 24, 2026 4:01 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 20 Filed by: Pulik Richard
June 23, 2026 9:18 PM - SEC Filing
Form 4 Roivant Sciences Ltd. For: Jun 20 Filed by: Humes Jennifer
June 23, 2026 9:16 PM - SEC Filing
Full Article List
